Chapter 30 : Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817572/9781555813291_Chap30-1.gif /docserver/preview/fulltext/10.1128/9781555817572/9781555813291_Chap30-2.gif


Malaria is the major parasitic disease in tropical developing countries, causing approximately 300 to 500 million febrile illnesses and at least 1.2 million deaths each year. Current antimalarial drugs and mosquito control programs constitute important measures against malaria, but these have limitations that must be met by research to develop new drugs, vaccines, and insecticides. The spread of drug-resistant malaria is a major obstacle for malaria control. Allelic replacement studies have demonstrated that chloroquine-sensitive parasites can be converted to the resistant phenotype using DNA transfection methods that introduce codons for these mutations into the expressed sequences of the wild-type gene. Involvement of as one of these genes is supported by studies showing that substitutions of Lys with Ile or Asn at amino acid position 76 of the transporter change parasite responses to both chloroquine and quinine. Quantitative trait loci (QTL) analysis of a genetic cross between clones has distinguished the additive effects of multiple genes in quinine response, including , , and a third gene that is predicted to encode a sodium-hydrogen exchanger. Pyrimethamine and sulfadoxine are structurally similar to dihydrofolate and p-aminobenzoic acid (PABA), respectively, and act as competitive inhibitors of the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) enzymes of .

Citation: Hayton K, Fairhurst R, Naudé B, Su X, Wellems T. 2005. Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, p 401-413. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch30

Key Concept Ranking

Parasitic Diseases
Antimalarial Drugs
Dihydrofolate Reductase Inhibitors
Malaria Life Cycle
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Changes in malaria death rates associated with the introduction of chloroquine and subsequent evolution of chloroquine-resistant malaria strains. (A) Malaria death rates in the 20th century. Dramatic reductions in mortality rates have been achieved outside sub-Saharan Africa. Mortality rates declined after the introduction of chloroquine but have risen again after the spread of chloroquine-resistant parasites across the continent. (Adapted from reference ). (B) Rise in mortality among children in the village of Mlomp, Senegal. Increased death rates associated with chloroquine resistance occurred chiefly among children <5 years old, the most susceptible age group in highly endemic areas. (Adapted from reference ).

Citation: Hayton K, Fairhurst R, Naudé B, Su X, Wellems T. 2005. Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, p 401-413. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch30
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

The malaria parasite life cycle (see text for descriptions).

Citation: Hayton K, Fairhurst R, Naudé B, Su X, Wellems T. 2005. Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, p 401-413. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch30
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Spread of chloroquine-resistant from at least five independent origins under drug pressure.

Citation: Hayton K, Fairhurst R, Naudé B, Su X, Wellems T. 2005. Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, p 401-413. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch30
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

The decline of antimalarial efficacy in Thailand. (Adapted from references and ).

Citation: Hayton K, Fairhurst R, Naudé B, Su X, Wellems T. 2005. Drug-Resistant Falciparum Malaria: Mechanisms, Consequences, and Challenges, p 401-413. In White D, Alekshun M, McDermott P (ed), Frontiers in Antimicrobial Resistance. ASM Press, Washington, DC. doi: 10.1128/9781555817572.ch30
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Arnold, K.,, T. H. Tran,, T. C. Nguyen,, H. P. Nguyen,, and P. Pham. 1990. A randomized comparative study of artemisinine (qinghaosu) suppositories and oral quinine in acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 84:499502.
2. Basco, L. K. 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for selfmedication. Am. J. Trop. Med. Hyg. 70:245250.
3. Basco, L. K.,, P. E. de Pecoulas,, C. M. Wilson,, J. Le Bras,, and A. Mazabraud. 1995. Point mutations in the dihydrofolate reductase- thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69:135138.
4. Basco, L. K.,, and J. Le Bras. 1992. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 47:521527.
5. Basco, L. K.,, J. Le Bras,, Z. Rhoades,, and C. M. Wilson. 1995. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol. Biochem. Parasitol. 74:157166.
6. Basco, L. K.,, R. Tahar,, and P. Ringwald. 1998. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob. Agents Chemother. 42:18111814.
7. Bayoumi, R. A.,, H. A. Babiker,, and D. E. Arnot. 1994. Uptake and efflux of chloroquine by chloroquine-resistant Plasmodium falciparum clones recently isolated in Africa. Acta Trop. 58:141149.
8. Bloland, P. B.,, E. M. Lackritz,, P. N. Kazembe,, J. B. O. Were,, R. Steketee,, and C. C. Campbell. 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J. Infect. Dis. 167: 932937.
9. Boudreau, E. F.,, H. K. Webster,, K. Pavanand,, and L. Thosingha. 1982. Type II mefloquine resistance in Thailand. Lancet 2:1335.
10. Brasseur, P.,, J. Kouamouo,, and P. Druilhe. 1991. Mefloquineresistant malaria induced by inappropriate quinine regimens? J. Infect. Dis. 164:625626.
11. Brasseur, P.,, J. Kouamouo,, R. Moyou-Somo,, and P. Druihe. 1992. Multi-drug resistant malaria in Cameroon in 1987- 1988. II. Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance. Am. J. Trop. Med. Hyg. 46:814.
12. Bray, P. G.,, R. E. Howells,, G. Y. Ritchie,, and S. A. Ward. 1992. Rapid chloroquine efflux phenotype in both chloroquine- sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energydependent drug accumulation. Biochem. Pharmacol. 44:13171324.
13. Bray, P. G.,, M. Mungthin,, R. G. Ridley,, and S. A. Ward. 1998. Access to hematin: the basis of chloroquine resistance. Mol. Pharmacol. 54:170179.
14. Brooks, D. R.,, P. Wang,, M. Read,, W. M. Watkins,, P. F. G. Sims,, and J. E. Hyde. 1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphate kinase:dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224:397405.
15. Canfield, C. J.,, M. Pudney,, and W. E. Gutteridge. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80: 373381.
16. Carter, R.,, and K. N. Mendis. 2002. Evolutionary and historical aspects of the burden of malaria. Clin. Microbiol. Rev. 15:564594.
17. Chaiyaroj, S. C.,, A. Buranakiti,, P. Angkasekwinai,, S. Looressuwan,, and A. F. Cowman. 1999. Analysis of mefloquine resistance and amplification of pfmdr1 in multidrug-resistant Plasmodium falciparum isolates from Thailand. Am. J. Trop. Med. Hyg. 61:780783.
18. Chen, G. X.,, C. Mueller,, M. Wendlinger,, and J. W. Zolg. 1987. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamineresistant clones of the human malaria parasite Plasmodium falciparum. Mol. Pharmacol. 31:430437.
19. Chen, N.,, D. E. Kyle,, C. Pasay,, E. V. Fowler,, J. Baker,, J. M. Peters,, and Q. Cheng. 2003. pfcrt allelic types with two novel amino acid mutations in chloroquine-resistant Plasmodium falciparum isolates from the Philippines. Antimicrob. Agents Chemother. 47:35003505.
20. Chiodini, P. L.,, C. P. Conlon,, D. B. Hutchinson,, J. A. Farquhar,, A. P. Hall,, T. E. Peto,, H. Birley,, and D. A. Warrell. 1995. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J. Antimicrob. Chemother. 36:10731078.
21. Chongsuphajaisiddhi, T.,, A. Subchareon,, S. Puangpartk,, and Y. Harinasutra. 1979. Treatment of falciparum malaria in Thai children. Southeast Asia J. Trop. Med. Public Health. 12: 418421.
22. Chou, A. C.,, R. Chevli,, and C. D. Fitch. 1980. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry 19: 15431549.
23. Clyde, D. F.,, R. M. Miller,, H. L. DuPont,, and R. B. Hornick. 1971. Antimalarial effects of tetracyclines in man. J. Trop. Med. Hyg. 74:238242.
24. Cooper, R. A.,, M. T. Ferdig,, X. Z. Su,, L. M. Ursos,, J. Mu,, T. Nomura,, H. Fujioka,, D. A. Fidock,, P. D. Roepe,, and T. E. Wellems. 2002. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 61:3542.
25. Cowman, A. F.,, D. Galatis,, and J. K. Thompson. 1994. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. USA 91: 11431147.
26. Cowman, A. F.,, S. Karcz,, D. Galatis,, and J. G. Culvenor. 1991. A P-glycoprotein homologue of Plasmodium falciparum is localised on the digestive vacuole. J. Cell Biol. 113:10331042.
27. Cowman, A. F.,, M. J. Morry,, B. A. Biggs,, G. A. M. Cross,, and S. J. Foote. 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 85:91099113.
28. Demar, M.,, and B. Carme. 2004. Plasmodium falciparum in vivo resistance to quinine: description of two RIII responses in French Guiana. Am. J. Trop. Med. Hyg. 70:125127.
29. Depoortere, E.,, J. P. Guthmann,, N. Sipilanyambe,, E. Nkandu,, F. Fermon,, S. Balkan,, and D. Legros. 2004. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Trop. Med. Int. Health 9:6267.
30. Djimde, A.,, O. K. Doumbo,, J. F. Cortese,, K. Kayentao,, S. Doumbo,, Y. Diourte,, A. Dicko,, X. Z. Su,, T. Nomura,, D. A. Fidock,, T. E. Wellems,, C. V. Plowe,, and D. Coulibaly. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257263.
31. Djimde, A.,, O. K. Doumbo,, R. W. Steketee,, and C. V. Plowe. 2001. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358:890891.
32. Djimde, A.,, C. V. Plowe,, S. Diop,, A. Dicko,, T. E. Wellems,, and O. Doumbo. 1998. Use of antimalarial drugs in Mali: policy versus reality. Am. J. Trop. Med. Hyg. 59:376379.
33. Djimde, A. A.,, O. K. Doumbo,, O. Traore,, A. B. Guindo,, K. Kayentao,, Y. Diourte,, S. Niare-Doumbo,, D. Coulibaly,, A. K. Kone,, Y. Cissoko,, M. Tekete,, B. Fofana,, A. Dicko,, D. A. Diallo,, T. E. Wellems,, D. Kwiatkowski,, and C. V. Plowe. 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 69:558563.
34. Doi, H.,, A. Kaneko,, W. Panjaitan,, and A. Ishii. 1989. Chemotherapeutic malaria control operation by single dose of Fansidar plus primaquine in North Sumatra, Indonesia. Southeast Asian J. Trop. Med. Public Health 20:341349.
35. Dorn, A.,, S. R. Vippagunta,, H. Matile,, A. Bubendorf,, J. L. Vennerstrom,, and R. G. Ridley. 1998. A comparison and analysis of several ways to promote haematin (haem) polymerisation and an assessment of its initiation in vitro. Biochem. Pharmacol. 55:737747.
36. Dorsey, G.,, M. R. Kamya,, A. Singh,, and P. J. Rosenthal. 2001. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J. Infect. Dis. 183:14171420.
37. Duraisingh, M. T.,, P. Jones,, I. Sambou,, L. von Seidlein,, M. Pinder,, and D. C. Warhurst. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:1323.
38. Dzekunov, S. M.,, L. M. B. Ursos,, and P. D. Roepe. 2000. Digestive vacuolar pH of intact intraerythrocyctic Plasmodium falciparum either sensitive or resistant to chloroquine. Mol. Biochem. Parasitol. 101:107124.
39. Eyles, D. E.,, C. C. Hoo,, M. Warren,, and A. A. Sandosham. 1963. Plasmodium falciparum resistant to chloroquine in Cambodia. Am. J. Trop. Med. Hyg. 12:840843.
40. Ferdig, M. T.,, R. A. Cooper,, J. Mu,, B. Deng,, D. A. Joy,, X. Z. Su,, and T. E. Wellems. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52: 985997.
41. Fidock, D. A.,, T. Nomura,, A. K. Talley,, R. A. Cooper,, S. M. Dzekunov,, M. T. Ferdig,, L. M. Ursos,, A. B. Sidhu,, B. Naude,, K. W. Deitsch,, X. Z. Su,, J. C. Wootton,, P. D. Roepe,, and T. E. Wellems. 2000. Mutations in the Plasmodium falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861871.
42. Fitch, C. D. 1970. Plasmodium falciparum in owl monkeys: drug resistance and chloroquine binding capacity. Science 169:289290.
43. Fivelman, Q. L.,, G. A. Butcher,, I. S. Adagu,, D. C. Warhurst,, and G. Pasvol. 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar. J. 1:14.
44. Foote, S. J.,, D. Galatis,, and A. F. Cowman. 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl Acad. Sci. USA 87:30143017.
45. Foote, S. J.,, J. K. Thompson,, A. F. Cowman,, and D. J. Kemp. 1989. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of Plasmodium falciparum. Cell 57:921930.
46. Fungladda, W.,, E. R. Honrado,, K. Thimasarn,, D. Kitayaporn,, J. Karbwang,, P. Kamolratanakul,, and R. Masngammueng. 1998. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull. World Health Organ. 76(Suppl. 1):5966.
47. Giboda, M.,, and M. B. Denis. 1988. Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro. J. Trop. Med. Hyg. 91:205211.
48. Harinasuta, T., Migasen, S., and Boonag, D. 1962. Chloroquine resistance in Plasmodium falciparum in Thailand. UNESCO First Regional Symposium on Scientific Knowledge of Tropical Parasites, Singapore University, Singapore.
49. Hien, T. T.,, C. Dolecek,, P. M. Pham,, T. D. Nguyen,, T. T. Nguyen,, H. T. Le,, T. H. Dong,, T. T. Tran,, K. Stepniewska,, N. J. White,, and J. Farrar. 2004. Dihydroartemisininpiperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363:1822.
50. Hii, J. L.,, Y. S. Vun,, K. F. Chin,, R. Chua,, S. Tambakau,, E. S. Binisol,, E. Fernandez,, N. Singh,, and M. K. Chan. 1987. The influence of permethrin-impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia. Med. Vet. Entomol. 1:397407.
51.International Artemisinin Study Group. 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:917.
52. Ittarat, W.,, A. L. Pickard,, P. Rattanasinganchan,, P. Wilairatana,, S. Looareesuwan,, K. Emery,, J. Low,, R. Udomsangpetch,, and S. R. Meshnick. 2003. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am. J. Trop. Med. Hyg. 68:147152.
53. Kaneko, A.,, G. Taleo,, M. Kalkoa,, S. Yamar,, T. Kobayakawa,, and A. Bjorkman. 2000. Malaria eradication on islands. Lancet 356:15601564.
54. Korsinczky, M.,, N. Chen,, B. Kotecka,, A. Saul,, K. Rieckmann,, and Q. Cheng. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44:21002108.
55. Krogstad, D. J.,, I. Y. Gluzman,, B. L. Herwaldt,, P. H. Schlesinger,, and T. E. Wellems. 1992. Energy dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum. Biochem. Pharmacol. 43:5762.
56. Krogstad, D. J.,, I. Y. Gluzman,, D. E. Kyle,, A. M. J. Oduola,, S. K. Martin,, W. K. Milhous,, and P. H. Schlesinger. 1987. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238:12831285.
57. Krudsood, S.,, K. Chalermrut,, C. Pengruksa,, S. Srivilairit,, U. Silachamroon,, S. Treeprasertsuk,, S. Kano,, G. M. Brittenham,, and S. Looareesuwan. 2003. Comparative clinical trial of twofixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/ Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 34:316321.
58. Kublin, J. G.,, J. F. Cortese,, E. M. Njunju,, R. A. Mukadam,, J. J. Wirima,, P. N. Kazembe,, A. A. Djimde,, B. Kouriba,, T. E. Taylor,, and C. V. Plowe. 2003. Reemergence of chloroquinesensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187:18701875.
59. Kublin, J. G.,, F. K. Dzinjalamala,, D. D. Kamwendo,, E. M. Malkin,, J. F. Cortese,, L. M. Martino,, R. A. Mukadam,, S. J. Rogerson,, A. G. Lescano,, M. E. Molyneux,, P. A. Winstanley,, P. Chimpeni,, T. E. Taylor,, and C. V. Plowe. 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil- dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185:380388.
60. Lell, B.,, and P. G. Kremsner. 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. 46:23152320.
61. Lemnge, M. M.,, H. A. Msangeni,, A. M. Ronn,, F. M. Salum,, P. H. Jakobsen,, J. I. Mhina,, J. A. Akida,, and I. C. Bygbjerg. 1997. Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania. Trans. R. Soc. Trop. Med. Hyg. 91:6873.
62. Lim, A. S. Y.,, D. Galatis,, and A. F. Cowman. 1996. Plasmodium falciparum: amplification and overexpression of pfmdr1 is not necessary for increased mefloquine resistance. Exp. Parasitol. 83:295303.
63. Liu, D. Q.,, R. J. Liu,, D. X. Ren,, D. Q. Gao,, C. Y. Zhang,, C. P. Qui,, X. Z. Cai,, C. F. Ling,, A. H. Song,, and X. Tang. 1995. Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Bull. World Health Organ. 73:483486.
64. Looareesuwan, S.,, C. Viravan,, H. K. Webster,, D. E. Kyle,, D. B. Hutchinson,, and C. J. Canfield. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54:6266.
65. Martin, S. K.,, A. M. Oduola,, and W. K. Milhous. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899901.
66. Massaga, J. J.,, A. Y. Kitua,, M. M. Lemnge,, J. A. Akida,, L. N. Malle,, A. M. Ronn,, T. G. Theander,, and I. C. Bygbjerg. 2003. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet 361:18531860.
67. McGready, R.,, T. Cho,, N. K. Keo,, K. L. Thwai,, L. Villegas,, S. Looareesuwan,, N. J. White,, and F. Nosten. 2001. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin. Infect. Dis. 33:20092016.
68. McIntosh, H. M.,, and P. Olliaro. 2000. Artemisinin derivatives for treating severe malaria. Cochrane Database Syst. Rev. CD000527.
69. Mehlotra, R. K.,, H. Fujioka,, P. D. Roepe,, O. Janneh,, L. M. Ursos,, V. Jacobs-Lorena,, D. T. McNamara,, M. J. Bockarie,, J. W. Kazura,, D. E. Kyle,, D. A. Fidock,, and P. A. Zimmerman. 2001. Evolution of a unique Plasmodium falciparum chloroquine- resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc. Natl Acad. Sci. USA 98:1268912694.
70. Menendez, C.,, E. Kahigwa,, R. Hirt,, P. Vounatsou,, J. J. Aponte,, F. Font,, C. J. Acosta,, D. M. Schellenberg,, C. M. Galindo,, J. Kimario,, H. Urassa,, B. Brabin,, T. A. Smith,, A. Y. Kitua,, M. Tanner,, and P. L. Alonso. 1997. Randomised placebocontrolled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350:844850.
71. Molineaux, L.,, and G. Gramiccia. 1980. The Garki Project. World Health Organization, Geneva.
72. Moore, D. V.,, and J. E. Lanier. 1961. Observations on two Plasmodium falciparum infections with abnormal response to chloroquine. Am. J. Trop. Med. Hyg. 10:59.
73. Mu, J.,, M. T. Ferdig,, X. Feng,, D. A. Joy,, J. Duan,, T. Furuya,, G. Subramanian,, L. Aravind,, R. A. Cooper,, J. C. Wootton,, M. Xiong,, and X. Z. Su. 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49:977989.
74. Nafo-Traore, F. 2004. Response to accusations of medical malpractice by WHO and the Global Fund. Lancet 363:397.
75. Nair, S.,, J. T. Williams,, A. Brockman,, L. Paiphun,, M. Mayxay,, P. N. Newton,, J. P. Guthmann,, F. M. Smithuis,, T. T. Hien,, N. J. White,, F. Nosten,, and T. J. Anderson. 2003. A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol. Biol. Evol. 20:15261536.
76. Newton, P.,, S. Proux,, M. Green,, F. Smithuis,, J. Rozendaal,, S. Prakongpan,, K. Chotivanich,, M. Mayxay,, S. Looareesuwan,, J. Farrar,, F. Nosten,, and N. J. White. 2001. Fake artesunate in Southeast Asia. Lancet 357:19481950.
77. Newton, P. N.,, A. Dondorp,, M. Green,, M. Mayxay,, and N. J. White. 2003. Counterfeit artesunate antimalarials in Southeast Asia. Lancet 362:169.
78. Ngo, T.,, M. Duraisingh,, M. Reed,, D. Hipgrave,, B. Biggs,, and A. F. Cowman. 2003. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. Am. J. Trop. Med. Hyg. 68:350356.
79. Nosten, F.,, T. T. Hien,, and N. J. White. 1998. Use of artemisinin derivatives for the control of malaria. Med. Trop. 58:4549.
80. Nosten, F.,, F. ter Kuile,, T. Chongsuphajaisiddhi,, C. Luxemburger,, H. K. Webster,, M. Edstein,, L. Phaipun,, K. L. Thew,, and N. J. White. 1991. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337:11401143.
81. Nosten, F.,, M. vanVugt,, R. Price,, C. Luxemburger,, K. L. Thway,, A. Brockman,, R. McGready,, F. ter Kuile,, S. Looareesuwan,, and N. J. White. 2000. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356:297302.
82. Nzila, A. M.,, E. K. Mberu,, J. Sulo,, H. Dayo,, P. A. Winstanley,, C. H. Sibley,, and W. M. Watkins. 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44:991996.
83. Nzila, A. M.,, E. Nduati,, E. K. Mberu,, C. H. Sibley,, S. A. Monks,, P. A. Winstanley,, and W. M. Watkins. 2000. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethaminesulfadoxine compared with the shorter-acting chlorproguanil/ dapsone on Kenyan Plasmodium falciparum. J. Inf. Dis. 181: 20232028.
84. Omar, S. A.,, I. S. Adagu,, and D. C. Warhurst. 2001. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine- pyrimethamine treatment failure? Trans. R. Soc. Trop. Med. Hyg. 95:315319.
85. Pages, F.,, J. P. Boutin,, J. B. Meynard,, A. Keundjian,, S. Ryfer,, L. Giurato,, and D. Baudon. 2002. Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop. Med. Int. Health 7:919924.
86. Peel, S. A.,, P. Bright,, B. Yount,, J. Handy,, and R. S. Baric. 1994. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the p-glycoprotein gene homologue (pfmdr) of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 51:648658.
87. Peters, W. (ed.). 1987. Chemotherapy and Drug Resistance in Malaria, 2nd ed., vol. 1 and 2. Academic Press, London, United Kingdom.
88. Peterson, D. S.,, W. K. Milhous,, and T. E. Wellems. 1990. Molecular basis to differential resistance to cycloguanil and pyrimethamine in falciparum malaria. Proc. Natl Acad. Sci. USA 87:30183022.
89. Peterson, D. S.,, D. Walliker,, and T. E. Wellems. 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl Acad. Sci. USA 85:91149118.
90. Price, R.,, G. Robinson,, A. Brockman,, A. Cowman,, and S. Krishna. 1997. Assessment of pfmdr1 gene copy number by tandem competitive polymerase chain reaction. Mol. Biochem. Parasitol. 85:161169.
91. Price, R.,, M. van Vugt,, L. Phaipun,, C. Luxemburger,, J. Simpson,, R. McGready,, F. ter Kuile,, A. Kham,, T. Chongsuphajaisiddhi,, N. J. White,, and F. Nosten. 1999. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60:547555.
92. Price, R. N. 2000. Artemisinin drugs: novel antimalarial agents. Expert. Opin. Investig. Drugs 9:18151827.
93. Price, R. N.,, C. Cassar,, A. Brockman,, M. Duraisingh,, M. van Vugt,, N. J. White,, F. Nosten,, and S. Krishna. 1999. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43:29432949.
94. Pukrittayakamee, S.,, A. Chantra,, S. Vanijanonta,, R. Clemens,, S. Looareesuwan,, and N. J. White. 2000. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob. Agents Chemother. 44:23952398.
95. Pukrittayakamee, S.,, W. Supanaranond,, S. Looareesuwan,, S. Vanijanonta,, and N. J. White. 1994. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans. R. Soc. Trop. Med. Hyg. 88:324327.
96. Reacher, M.,, C. C. Campbell,, J. Freeman,, E. B. Doberstyn,, and A. D. Brandling-Bennett. 1980. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulphadoxine (Fansidar). A study of alternate regimes in Eastern Thailand. Lancet 2:10661069.
97. Reed, M. B.,, K. J. Saliba,, S. R. Caruana,, K. Kirk,, and A. F. Cowman. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906909.
98. Richards, W. H. G. 1966. Antimalarial activity of sulphonamides and a sulphone, singly and in combination with pyrimethamine, against drug resistant and normal strains of laboratory plasmodia. Nature 212:14941495.
99. Ritchie, G. Y.,, M. Mungthin,, J. E. Green,, P. G. Bray,, S. R. Hawley,, and S. A. Ward. 1996. In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Mol. Biochem. Parasitol. 83:3546.
100. Roper, C.,, R. Pearce,, B. Bredenkamp,, J. Gumede,, C. Drakeley,, F. Mosha,, D. Chandramohan,, and B. Sharp. 2003. Antifolate antimalarial resistance in southeast Africa: a population- based analysis. Lancet 361:11741181.
101. Sanchez, C. P.,, S. Wunsch,, and M. Lanzer. 1997. Identification of a chloroquine importer in Plasmodium falciparum: differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. J. Biol. Chem. 272:26522658.
102. Schellenberg, D.,, C. Menendez,, E. Kahigwa,, J. Aponte,, J. Vidal,, M. Tanner,, H. Mshinda,, and P. Alonso. 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357:14711477.
103. Schwenke, A.,, C. Brandts,, J. Philipps,, S. Winkler,, W. H. Wernsdorfer,, and P. G. Kremsner. 2001. Declining chloroquine resistance of Plasmodium falciparum in Lambarene, Gabon from 1992 to 1998. Wien. Klin. Wochenschr. 113:6364.
104. Shulman, C. E.,, E. K. Dorman,, F. Cutts,, K. Kawuondo,, J. N. Bulmer,, N. Peshu,, and K. Marsh. 1999. Intermittent sulphadoxine- pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 353:632636.
105. Sidhu, A. B.,, D. Verdier-Pinard,, and D. A. Fidock. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210213.
106. Siriwaraporn, W. 1998. Dihydrofolate reductase and antifolate resistance in malaria. Drug Resistance Updates 1:397406.
107. Skinner-Adams, T., and T. M. Davis. 1999. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob. Agents Chemother. 43:13041306.
108. Srivastava, I. K.,, J. M. Morrisey,, E. Darrouzet,, F. Daldal,, and A. B. Vaidya. 1999. Resistance mutations reveal the atovaquone- binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33:704711.
109. Srivastava, I. K.,, H. Rottenberg,, and A. B. Vaidya. 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272:39613966.
110. Srivastava, I. K.,, and A. B. Vaidya. 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43:13341339.
111. Sulo, J.,, P. Chimpeni,, J. Hatcher,, J. G. Kublin,, C. V. Plowe,, M. E. Molyneux,, K. Marsh,, T. E. Taylor,, W. M. Watkins,, and P. A. Winstanley. 2002. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360:11361143.
112. Trape, J. F.,, G. Pison,, M. P. Preziosi,, C. Enel,, L. A. Desgrees du,, V. Delaunay,, B. Samb,, E. Lagarde,, J. F. Molez,, and F. Simondon. 1998. Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. III 321:689697.
113. Trape, J. F.,, C. Rogier,, L. Konate,, N. Diagne,, H. Bouganali,, B. Canque,, F. Legros,, A. Badji,, G. Ndiaye,, P. Ndiaye,, K. Brahimi,, O. Faye,, P. Druilhe,, and L. P. daSilva. 1994. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am. J. Trop. Med. Hyg. 51:123137.
114. Triglia, T.,, and A. F. Cowman. 1994. Primary structure and expression of the dihydropteroate synthase gene of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 91:71497153.
115. Triglia, T.,, J. G. T. Menting,, C. Wilson,, and A. F. Cowman. 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94:1394413949.
116. Triglia, T.,, P. Wang,, P. F. G. Sims,, J. E. Hyde,, and A. F. Cowman. 1998. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17:38073815.
117. von Seidlein, L.,, and B. M. Greenwood. 2003. Mass administrations of antimalarial drugs. Trends Parasitol. 19:452460.
118. von Seidlein, L.,, G. Walraven,, P. J. Milligan,, N. Alexander,, F. Manneh,, J. L. Deen,, R. Coleman,, M. Jawara,, S. W. Lindsay,, C. Drakeley,, S. DeMartin,, P. Olliaro,, S. Bennett,, M. SchimvanderLoeff,, K. Okunoye,, G. A. Targett,, K. P. McAdam,, J. F. Doherty,, B. M. Greenwood,, and M. Pinder. 2003. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community- randomized, placebo-controlled trial in The Gambia. Trans. R. Soc. Trop. Med. Hyg. 97:217225.
119. Wang, P.,, C.-S. Lee,, R. Bayoumi,, A. Djimde,, O. Doumbo,, G. Swedberg,, L. Duc Dao,, H. Mshinda,, M. Tanner,, W. M. Watkins,, P. F. G. Sims,, and J. E. Hyde. 1997. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol. 89:161177.
120. Warsame, M.,, W. H. Wernsdorfer,, D. Payne,, and A. Bjorkman. 1991. Susceptibility of Plasmodium falciparum in vitro to chloroquine, mefloquine, quinine and sulfadoxine/pyrimethamine in Somalia: relationships between the responses to the different drugs. Trans. R. Soc. Trop. Med. Hyg. 85:565569.
121. Watkins, W. M.,, D. G. Sixsmith,, J. D. Chulay,, and H. C. Spencer. 1985. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol. Biochem. Parasitol. 14:5561.
122. Wellems, T. E.,, L. J. Panton,, I. Y. Gluzman,, V. E. do Rosario,, R. W. Gwadz,, A. Walker-Jonah,, and D. J. Krogstad. 1990. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345:253255.
123. Wellems, T. E.,, and C. V. Plowe. 2001. Chloroquine-resistant malaria. J. Infect. Dis. 184:770776.
124. White, N. J., 1996. Malaria, p. 10871164. In G. C. Cook (ed.), Manson’s Tropical Diseases. W. B. Saunders Company Ltd, London, United Kingdom.
125. White, N. J.,, F. Nosten,, S. Looareesuwan,, W. M. Watkins,, K. Marsh,, R. W. Snow,, G. Kokwaro,, J. Ouma,, T. T. Hien,, M. E. Molyneux,, T. E. Taylor,, C. I. Newbold,, T. K. Ruebush II,, M. Danis,, B. M. Greenwood,, R. M. Anderson,, and P. L. Olliaro. 1999. Averting a malaria disaster. Lancet 353:19651967.
126. Wilson, C. M.,, A. E. Serrano,, A. Wasley,, M. P. Bogenschutz,, A. H. Shankar,, and D. F. Wirth. 1989. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 244:11841186.
127. Wilson, C. M.,, S. K. Volkman,, S. Thaithong,, R. K. Martin,, D. E. Kyle,, W. K. Milhous,, and D. F. Wirth. 1993. Amplification of pfmdr-1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. 57:151160.
128. Wongsrichanalai, C.,, A. L. Pickard,, W. H. Wernsdorfer,, and S. R. Meshnick. 2002. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2:209218.
129. Wongsrichanalai, C.,, J. Sirichaisinthop,, J. J. Karwacki,, K. Congpuong,, R. S. Miller,, L. Pang,, and K. Thimasarn. 2001. Drug resistant malaria on the Thai-Myanmar and Thai- Cambodian borders. Southeast Asian J. Trop. Med. Public Health 32:4149.
130. Wootton, J. C.,, X. Feng,, M. T. Ferdig,, R. A. Cooper,, J. Mu,, D. I. Baruch,, A. J. Magill,, and X. Z. Su. 2002. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418:320323.
131.World Health Organization. The World Health Report 2003. World Health Organization, Geneva, Switzerland.
132. Wu, Y. M.,, L. A. Kirkman,, and T. E. Wellems. 1996. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc. Natl Acad. Sci. USA 93:11301134.
133. Yayon, A.,, Z. I. Cabantchik,, and H. Ginsburg. 1984. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3:26952700.
134. Zhang, Y.,, and E. Hempelmann. 1987. Lysis of malarial parasites and erythrocytes by ferriprotoporphyrin IX-chloroquine and the inhibition of this effect by proteins. Biochem. Pharmacol. 36:12671273.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error